Literature DB >> 10323599

Effect of potassium channel modulators in mouse forced swimming test.

N Galeotti1, C Ghelardini, B Caldari, A Bartolini.   

Abstract

1. The effect of intracerebroventricular (i.c.v.) administration of different potassium channel blockers (tetraethylammonium, apamin, charybdotoxin, gliquidone), potassium channel openers (pinacidil, minoxidil, cromakalim) and aODN to mKv1.1 on immobility time was evaluated in the mouse forced swimming test, an animal model of depression. 2. Tetraethylammonium (TEA; 5 microg per mouse i.c.v.), apamin (3 ng per mouse i.c.v.), charybdotoxin (1 microg per mouse i.c.v.) and gliquidone (6 microg per mouse i.c.v.) administered 20 min before the test produced anti-immobility comparable to that induced by the tricyclic antidepressants amitriptyline (15 mg kg(-1) s.c.) and imipramine (30 mg kg(-1) s.c.). 3. By contrast pinacidil (10-20 microg per mouse i.c.v.), minoxidil (10-20 microg per mouse i.c.v.) and cromakalim (20-30 microg per mouse i.c.v.) increased immobility time when administered in the same experimental conditions. 4. Repeated administration of an antisense oligonucleotide (aODN) to the mKv1.1 gene (1 and 3 nmol per single i.c.v. injection) produced a dose-dependent increase in immobility time of mice 72 h after the last injection. At day 7, the increasing effect produced by aODN disappeared. A degenerate mKv1.1 oligonucleotide (dODN), used as control, did not produce any effect in comparison with saline- and vector-treated mice. 5. At the highest effective dose, potassium channels modulators and the mKv1.1 aODN did not impair motor coordination, as revealed by the rota rod test, nor did they modify spontaneous motility as revealed by the Animex apparatus. 6. These results suggest that modulation of potassium channels plays an important role in the regulation of immobility time in the mouse forced swimming test.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323599      PMCID: PMC1565937          DOI: 10.1038/sj.bjp.0702467

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Behavioural despair in rats: a new model sensitive to antidepressant treatments.

Authors:  R D Porsolt; G Anton; N Blavet; M Jalfre
Journal:  Eur J Pharmacol       Date:  1978-02-15       Impact factor: 4.432

Review 2.  Potassium channel toxins.

Authors:  P N Strong
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Expression of a cloned rat brain potassium channel in Xenopus oocytes.

Authors:  M J Christie; J P Adelman; J Douglass; R A North
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

4.  Charybdotoxin, a protein inhibitor of single Ca2+-activated K+ channels from mammalian skeletal muscle.

Authors:  C Miller; E Moczydlowski; R Latorre; M Phillips
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

Review 5.  The pharmacology of potassium channels and their therapeutic potential.

Authors:  N S Cook
Journal:  Trends Pharmacol Sci       Date:  1988-01       Impact factor: 14.819

6.  Cloning of a probable potassium channel gene from mouse brain.

Authors:  B L Tempel; Y N Jan; L Y Jan
Journal:  Nature       Date:  1988-04-28       Impact factor: 49.962

Review 7.  Is the forced swimming test a suitable model for revealing antidepressant activity?

Authors:  F Borsini; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 8.  The validity of animal models of depression.

Authors:  P Willner
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  A family of three mouse potassium channel genes with intronless coding regions.

Authors:  K G Chandy; C B Williams; R H Spencer; B A Aguilar; S Ghanshani; B L Tempel; G A Gutman
Journal:  Science       Date:  1990-02-23       Impact factor: 47.728

10.  Molecular basis of functional diversity of voltage-gated potassium channels in mammalian brain.

Authors:  W Stühmer; J P Ruppersberg; K H Schröter; B Sakmann; M Stocker; K P Giese; A Perschke; A Baumann; O Pongs
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

View more
  13 in total

Review 1.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

2.  CHRONIC NEONATAL DIAZOXIDE THERAPY IS NOT ASSOCIATED WITH ADVERSE EFFECTS.

Authors:  Michele M Cox; Christopher C Wendler; Ildiko Erdelyi; Amanda Beck; Caroline Zeiss; Scott A Rivkees
Journal:  Online J Biol Sci       Date:  2014-01-01

3.  A mutant of the Buthus martensii Karsch antitumor-analgesic peptide exhibits reduced inhibition to hNav1.4 and hNav1.5 channels while retaining analgesic activity.

Authors:  Yijia Xu; Xiangxue Meng; Xue Hou; Jianfang Sun; Xiaohua Kong; Yuqi Sun; Zeyu Liu; Yuanyuan Ma; Ye Niu; Yongbo Song; Yong Cui; Mingyi Zhao; Jinghai Zhang
Journal:  J Biol Chem       Date:  2017-09-18       Impact factor: 5.157

4.  Evaluation of the pharmacological involvement of ATP-sensitive potassium (KATP) channels in the antidepressant-like effects of topiramate on mice.

Authors:  Saeed Shakiba; Mehdi Rezaee; Khashayar Afshari; Kiarash Kazemi; Khadijeh-Alsadat Sharifi; Nazgol-Sadat Haddadi; Arvin Haj-Mirzaian; Aida Kamalian; Seyedeh Zarifeh Jazaeri; Kent Richter; Ahmad Reza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-03-04       Impact factor: 3.000

5.  Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine.

Authors:  S Y Yeung; J A Millar; A Mathie
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

6.  Differential effects of K(ATP) channel blockers on [(3)H]-noradrenaline overflow after short- and long-term exposure to (+)-oxaprotiline or desipramine.

Authors:  Klaus Eckhardt; Patrick Roth; Thomas Günter; Sascha Schmidt; Thomas J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-18       Impact factor: 3.000

7.  Curcumin and n-acetylcysteine cocrystal produced with supercritical solvent: characterization, solubility, and preclinical evaluation of antinociceptive and anti-inflammatory activities.

Authors:  Alessandro R Paulazzi; Bianca O Alves; Gabriela A L Zilli; Aline E Dos Santos; Fernanda Petry; Krissie D Soares; Letícia J Danielli; Jefferson Pedroso; Miriam A Apel; Gean Pablo S Aguiar; Anna M Siebel; J Vladimir Oliveira; Liz Girardi Müller
Journal:  Inflammopharmacology       Date:  2022-01-10       Impact factor: 4.473

8.  Evidence for the Involvement of Potassium Channel Inhibition in the Antidepressant-Like Effects of Hesperidin in the Tail Suspension Test in Mice.

Authors:  Franciele Donato; Carlos Borges Filho; Renata Giacomeli; Elza Eliza Tenório Alvater; Lucian Del Fabbro; Michele da Silva Antunes; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Leandro Cattelan Souza; Silvana Peterini Boeira; Cristiano Ricardo Jesse
Journal:  J Med Food       Date:  2015-02-03       Impact factor: 2.786

Review 9.  Physiology and Therapeutic Potential of SK, H, and M Medium AfterHyperPolarization Ion Channels.

Authors:  Deepanjali Dwivedi; Upinder S Bhalla
Journal:  Front Mol Neurosci       Date:  2021-06-03       Impact factor: 5.639

10.  Effects of fluoxetine on protein expression of potassium ion channels in the brain of chronic mild stress rats.

Authors:  Chunlin Chen; Ling Wang; Xianfang Rong; Weiping Wang; Xiaoliang Wang
Journal:  Acta Pharm Sin B       Date:  2014-12-30       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.